| pubmed-article:6135146 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6135146 | lifeskim:mentions | umls-concept:C0008286 | lld:lifeskim |
| pubmed-article:6135146 | lifeskim:mentions | umls-concept:C0040979 | lld:lifeskim |
| pubmed-article:6135146 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:6135146 | lifeskim:mentions | umls-concept:C2003941 | lld:lifeskim |
| pubmed-article:6135146 | lifeskim:mentions | umls-concept:C0599756 | lld:lifeskim |
| pubmed-article:6135146 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:6135146 | pubmed:dateCreated | 1983-8-11 | lld:pubmed |
| pubmed-article:6135146 | pubmed:abstractText | Trifluoperazine and chlorpromazine inhibited in a dose-dependent manner the stimulation of glycogenolysis, gluconeogenesis, and ureogenesis due to alpha 1-adrenergic stimulation in rat hepatocytes. In contrast, the antipsychotic agents were unable to block the inhibition of adenylate cyclase due to alpha 2-adrenergic activation in hamster adipocytes. Binding experiments showed that trifluoperazine and chlorpromazine at low concentrations displaced tritiated dihydroergocryptine binding from rat liver membranes (alpha 1-adrenergic sites), whereas very large concentrations of the phenothiazine derivatives were required to displace dihydroergocryptine from hamster adipocyte membranes (alpha 2-adrenergic sites). It is concluded that chlorpromazine and trifluoperazine are much more potent at alpha 1- than at alpha 2-adrenergic receptors. The use of rat hepatocytes and hamster adipocytes to study the alpha-adrenergic subtype selectivity of drugs is proposed. | lld:pubmed |
| pubmed-article:6135146 | pubmed:language | eng | lld:pubmed |
| pubmed-article:6135146 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6135146 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:6135146 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6135146 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6135146 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6135146 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6135146 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6135146 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6135146 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6135146 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6135146 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:6135146 | pubmed:issn | 0026-895X | lld:pubmed |
| pubmed-article:6135146 | pubmed:author | pubmed-author:García-SáinzJ... | lld:pubmed |
| pubmed-article:6135146 | pubmed:author | pubmed-author:Villalobos-Mo... | lld:pubmed |
| pubmed-article:6135146 | pubmed:author | pubmed-author:Huerta-Bahena... | lld:pubmed |
| pubmed-article:6135146 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6135146 | pubmed:volume | 23 | lld:pubmed |
| pubmed-article:6135146 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6135146 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:6135146 | pubmed:pagination | 67-70 | lld:pubmed |
| pubmed-article:6135146 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:6135146 | pubmed:meshHeading | pubmed-meshheading:6135146-... | lld:pubmed |
| pubmed-article:6135146 | pubmed:meshHeading | pubmed-meshheading:6135146-... | lld:pubmed |
| pubmed-article:6135146 | pubmed:meshHeading | pubmed-meshheading:6135146-... | lld:pubmed |
| pubmed-article:6135146 | pubmed:meshHeading | pubmed-meshheading:6135146-... | lld:pubmed |
| pubmed-article:6135146 | pubmed:meshHeading | pubmed-meshheading:6135146-... | lld:pubmed |
| pubmed-article:6135146 | pubmed:meshHeading | pubmed-meshheading:6135146-... | lld:pubmed |
| pubmed-article:6135146 | pubmed:meshHeading | pubmed-meshheading:6135146-... | lld:pubmed |
| pubmed-article:6135146 | pubmed:meshHeading | pubmed-meshheading:6135146-... | lld:pubmed |
| pubmed-article:6135146 | pubmed:meshHeading | pubmed-meshheading:6135146-... | lld:pubmed |
| pubmed-article:6135146 | pubmed:meshHeading | pubmed-meshheading:6135146-... | lld:pubmed |
| pubmed-article:6135146 | pubmed:meshHeading | pubmed-meshheading:6135146-... | lld:pubmed |
| pubmed-article:6135146 | pubmed:meshHeading | pubmed-meshheading:6135146-... | lld:pubmed |
| pubmed-article:6135146 | pubmed:meshHeading | pubmed-meshheading:6135146-... | lld:pubmed |
| pubmed-article:6135146 | pubmed:meshHeading | pubmed-meshheading:6135146-... | lld:pubmed |
| pubmed-article:6135146 | pubmed:meshHeading | pubmed-meshheading:6135146-... | lld:pubmed |
| pubmed-article:6135146 | pubmed:meshHeading | pubmed-meshheading:6135146-... | lld:pubmed |
| pubmed-article:6135146 | pubmed:year | 1983 | lld:pubmed |
| pubmed-article:6135146 | pubmed:articleTitle | Trifluoperazine and chlorpromazine antagonize alpha 1- but not alpha2- adrenergic effects. | lld:pubmed |
| pubmed-article:6135146 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:6135146 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6135146 | lld:pubmed |
